Lo Chihchieh, Cao Lideng, Lin Yuanyou, Wang Hang
Department of Oral and Maxillofacial Surgery and State Key Laboratory of Oral Diseases, Sichuan University West China College of Stomatology, Chengdu, Sichuan, China.
J Cosmet Dermatol. 2024 Dec;23(12):3828-3835. doi: 10.1111/jocd.16550. Epub 2024 Sep 21.
Autologous fat grafting is a widely used technique in plastic and reconstructive surgery for soft tissue augmentation. Despite its advantages, the primary limitation is the unpredictable retention rate of transplanted fat. Recent studies suggest that botulinum toxin type A (BTX-A) can enhance fat graft survival by promoting angiogenesis and muscle paralysis.
This review explores the potential of BTX-A as an adjuvant in autologous fat grafting, providing insights into its mechanisms, benefits, and the need for further clinical validation.
PATIENTS/METHODS: A literature review was conducted using PubMed, Web of Science, MEDLINE, and Embase. Keywords related to BTX-A, fat grafting, fat graft survival, and angiogenesis were used. Comparative studies reporting histological changes following BTX-A application in fat grafting were included. Exclusion criteria involved case reports with fewer than three animals, reviews, and letters.
The initial search yielded 108 articles, with seven experimental studies meeting the criteria. These studies demonstrated that BTX-A enhances fat graft retention by promoting vascularization and adipose-derived stem cell differentiation. However, these results are mainly based on small animal models.
While BTX-A shows promise in improving autologous fat grafting outcomes, its efficacy and safety in humans need validation through large-scale clinical trials. Translating these preclinical findings into human trials is crucial to establish standardized protocols and optimize clinical outcomes. Future research should focus on optimizing dosage and injection sites, conducting long-term follow-up studies, and performing multicenter trials to verify the findings.
自体脂肪移植是整形和重建外科中广泛用于软组织填充的技术。尽管具有诸多优点，但其主要局限性在于移植脂肪的留存率不可预测。近期研究表明，A型肉毒毒素（BTX-A）可通过促进血管生成和肌肉麻痹来提高脂肪移植的存活率。
本综述探讨BTX-A作为自体脂肪移植辅助剂的潜力，深入了解其作用机制、益处以及进一步临床验证的必要性。
患者/方法：使用PubMed、科学网、医学期刊数据库和Embase进行文献综述。使用了与BTX-A、脂肪移植、脂肪移植存活率和血管生成相关的关键词。纳入了报告BTX-A应用于脂肪移植后组织学变化的比较研究。排除标准包括动物数量少于三只的病例报告、综述和信函。
初步检索得到108篇文章，其中七项实验研究符合标准。这些研究表明，BTX-A通过促进血管化和脂肪来源干细胞分化来提高脂肪移植的留存率。然而，这些结果主要基于小动物模型。
虽然BTX-A在改善自体脂肪移植效果方面显示出前景，但其在人体中的疗效和安全性需要通过大规模临床试验进行验证。将这些临床前研究结果转化为人体试验对于建立标准化方案和优化临床结果至关重要。未来的研究应侧重于优化剂量和注射部位、进行长期随访研究以及开展多中心试验以验证研究结果。
